AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Trigger Timing in Ovarian Stimulations

RecruitingNAAges 18 Years - 42 YearsFemalePeking University Third Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The use of antagonist ovulation stimulation program is increasing year by year, because of its convenience, flexibility, and prevention effect of ovarian hyperstimulation syndrome. However, many researchers and clinicians believe that the clinical outcomes of antagonist regimens are worse than those of classical long-term regimens. Studies showed that the reasons for that maybe antagonist protocol results in poor effect on oocytes maturation or endometrial receptivity. At present, the trigger time of antagonist regimen is more than three follicles with diameters of โ‰ฅ17 mm, which makes the duration of gonadotrophin application in antagonist regimen is shorter than that of long regimen. Whether the trigger time of antagonist regimen is too early to cause adverse effects on oocytes, embryos and eventual clinical outcomes is unknown. This study hopes to compare regular trigger timing and 1

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age: โ‰ฅ18 and \<42 years old * AFC: โ‰ฅ5 and \<20 * AMH: โ‰ฅ1.1 ng/mL and \<2.5 ng/mL * BMI: โ‰ฅ18.5 Kg/m2 and \<29 Kg/m * First or second ART cycle * Regular menstrual cycles (between 22 and 35 days) * Two ovaries present * Planned for single or double day 3 transfer * Infertile couples scheduled for their first IVF/ICSI cycle with fixed antagonist protocol. * Informed consent obtained. Exclusion Criteria: * Women with contraindication for IVF or ICSI, such as poorly controlled type 1 or type 2 diabetes mellitus; undiagnosed liver disease or dysfunction (based on serum liver enzyme test results); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus or cerebrovascular accident; uncontrolled hypertension or known symptomatic heart disease; history of (or suspected) cervical carcinoma, endometrial carcinoma or breast carcinoma; and undiagnosed vaginal bleeding. * Previous history of poor ovarian response (\<4 oocytes retrieved) with a maximal dose of OS (โ‰ฅ300 IU/day) or OHSS, regardless of gonadotropin dose * Known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis) * Repeated miscarriages (\>2 previous biochemical pregnancies or \>2 spontaneous miscarriages) * Recurrent implantation failure (\>3 failed cycles with good quality embryos) * PCOS * Untreated thyroid disfunction * Administration of exogenous E2, P4 or gonadotropins in the preceding menstrual cycle * Active female smoking * Ongoing pregnancy * Women who have previously enrolled in the trial * Those unable to comprehend the investigational nature of the proposed study * either male partner or female partner has to receive donor sperm or donor eggs. * Either male partner or female partner has to receive PGD and PGS.
๐Ÿ’Š

What it tests

  • 1๏ฝž2 days later trigger than regular timing
๐Ÿ“

Where

1 site
Peking Univesity Third Hospital
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy